Gastrointestinal mesenchymal tumors are the most common mesenchymal tumors of the gastrointestinal tract originating from mesodermal tissues and were first named by Mazur et al. in 1983 after their discovery by electron microscopy and immunohistochemistry. 60-70% of GISTs occur in the stomach and surgical resection is the treatment of choice. Gastric mesenchymal tumors are mainly found in the gastric body (40%), sinus (25%), and cardia (25%). The diagnosis of gastric mesenchymal tumor is mainly based on barium meal imaging of upper gastrointestinal tract, gastroscopy, ultrasound endoscopy, CT, etc. The combination of two or more imaging diagnoses is more significant, especially EUS is more valuable for the diagnosis of gastric mesenchymal tumor, and positive CD117 and CD34 markers are the most valuable basis for the diagnosis of mesenchymal tumor. Since conventional gastroscopy is difficult to characterize submucosal lesions, it is difficult to determine the benignity and malignancy of gastric mesenchymal tumors before surgery. The treatment of gastric mesenchymal tumor is mainly local resection, including gastroscopic treatment, open treatment, and trans-laparoscopic treatment. Gastroscopic treatment is often difficult to remove the tumor completely, so it is less used clinically; open surgery can remove the tumor completely, but there are disadvantages such as difficulty in localization when the tumor is small, large surgical trauma, more intraoperative bleeding, slow postoperative recovery and long hospital stay, etc. Laparoscopic surgery has no such disadvantages and is the best measure to treat gastric mesenchymal tumor. However, for intracavitary type, especially for small tumors, it is more difficult to locate the tumor when using this procedure. Especially for the gastric interstitial tumor near the pylorus and cardia, it is possible to remove the tumor completely with minimal invasion while preserving the function of the pylorus and cardia.